Stock comparison
BioCryst Pharmaceuticals
BCRX
Market cap
$2.14B
Sector
Healthcare
Overall winner
Mettler-Toledo International
BCRX 0–7 MTD
Mettler-Toledo International
MTD
Market cap
$23.33B
Sector
Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
BCRXvsMTD
40D
69B
24F
65B
40D
63C
60C
66B
4F
68B
35D
74B
41D
70B
Side-by-side metrics
| Metric | BCRX | MTD |
|---|---|---|
| Market cap | $2.14B | $23.33B |
| P/E (TTM) | - | 25.3x |
| EV/EBIT | 7.6x | 21.6x |
| ROIC (TTM) | -121.96% | 36.09% |
| Gross margin | 18.89% | 57.79% |
| Net margin | -51.71% | 21.4% |
| Revenue CAGR 5y | 53.6% | 2.01% |
| EPS CAGR 5y | - | 6.12% |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BCRX leads on
- P/E (TTM)-vs 25.3x+119%
- Revenue CAGR 5y53.6%vs 2.01%+96%
- EV/EBIT7.6xvs 21.6x+65%
MTD leads on
- Net margin21.4%vs -51.71%+141%
- ROIC (TTM)36.09%vs -121.96%+130%
- Debt / Equity-vs -+97%
- Market cap$23.33Bvs $2.14B+91%
More like BCRX
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.